Concerto's clinical trial, ENS-002 for Atopic Dermatitis in Adults, is now recruiting.More information
About Us
Reinventing humanity’s relationship with microbes.
Latest News & Press
Dermatology Times • 11 20 2024
Concerto Biosciences Doses First Participant in Phase 1 Trial of ENS-002, a Microbiome-Based Therapy for Atopic Dermatitis
MSN • 11 20 2024
Concerto doses first subject in Phase I trial of ENS-002 for atopic dermatitis
From Concerto • 11 19 2024
Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis
Bio.News • 7 11 2024
NIH Innovation Zone 2024: Concerto Biosciences illuminates collaboration of microbes
From Concerto • 6 26 2024
Concerto Biosciences Receives FDA Investigational New Drug Clearance for Live Biotherapeutic Product to Treat Atopic Dermatitis
Dermatology Times • 6 26 2024
FDA Grants Investigational New Drug Clearance for Ensemble No.2 for Phase 1 Atopic Dermatitis Trial
Our Mission
We create safe, effective microbial products for our world.
First came antibiotics. Then came genetic engineering. Concerto is catalyzing a third wave of microbial technologies to capture what microbes do best: Protect the health of our bodies, our food, and our planet. Accessing these microbial ecology-inspired products requires rigorous discovery science, a strong collaborative culture, and an unyielding commitment to improvement.Our Values
Grow by experimenting
Work rigorously
Listen intently
Act with compassion
Permission to Play
Concerto embraces a foundational set of additional values that we believe ought to be evident in any startup.Harness microbial ecology with Concerto to develop new, transformative products.
Partner With UsMicrobes, like humans, are stronger together than they ever could be alone.
Visit Us
750 Main Street
Cambridge, MA 02139
© 2024 Concerto Biosciences, Inc. All rights reserved.